- Effectiveness of improved treatment of inflamatory bowel disiseases in infants
Effectiveness of improved treatment of inflamatory bowel disiseases in infants
PERINATOLOGIYA I PEDIATRIYA.2015.1(61):87–94;doi10.15574/PP.2015.61.87
Effectiveness of improved treatment of inflamatory bowel disiseases in infants
Marushko R. V., Shadrin O. G., Marushko K. R.
SI «Institute of Pediatrics, Obstetrics and Gynecology, National Academy of Medical Science of Ukraine» Kyiv, Ukraine
Actually is required to improve the treatment of chronic inflammatory bowel disease in infants on the principles of safety of therapeutic interventions and the impact on the basic pathogenetic mechanisms involved in the formation of the pathology of the bowel.
Purpose — to evaluate the effectiveness of improved treatment of chronic non-specific non-ulcered colitis in infants using functional foods (pro-, prebiotics, omega-3 long-chain polyunsaturated fatty acids, L-carnitine), hepatoprotectors and alternative formulas.
Patients and methods. A total of 114 infants (from 9 months up to 3 years of life) with chronic non-specific non-ulcerated colitis were studded. Researched the effectiveness of improved treatment using pro-, prebiotics, omega-3 long chain polyunsaturated fatty acids, L-carnitine, hepatoprotectors and semi-elemental formula of chronic non-specific non-ulcerated colitis on the basis of clinical and laboratory research methods, including bacteriological and immunological (TNF-a, ITF in serum, SIgA in coprofiltrates). Were used chronic non-specific non-ulcerated colitis activity index and the index of endoscopic changes of the intestinal mucosa during the treatment in infants.
Results. It is shown that the use of functional foods as multiprobiotics, prebiotics, omega-3 polyunsaturated fatty acids and enhancing cellular energy pro-vitamins as well as hepatoprotectors and alternative formulas in the treatment of chronic colitis in infants contributes to a significant improvement in the results of chronic non-specific non-ulcered colitis treatment, more rapidly elimination of main symptoms and increase the number of positive results of treatment in infants with chronic non-specific non-ulcerated colitis (80.4% versus 55.2%).
Conclusions. Results of the study allow us to recommend the use of elaborated improved treatment in infants with chronic non-specific non-ulcerated colitis on different levels of child healthcare.
Key words: infants, chronic non-specific non-ulcerated colitis, functional food.
REFERENCES:
1. Белоусова ОЮ. 2013. Хронический неспецифический неязвенный колит у детей. Перинатология и педиатрия. 1: 87—91.
2. Бєлоусова ОЮ. 2008. Хронічний коліт та синдром подразненого кишечнику у дітей: питання дефініції. Напрямки розвитку педіатрії на сучасному етапі. Київ: 183—184.
3. Ключников СО. 2007. Перспективы применения L-карнитина в педиатрии. Consilium Medicum, Педиатрия. 2: 116—119.
4. Марушко РВ. 2013. Kлініко-іммунологічні особливості хронічного неспецифічного невиразкового коліту у дітей раннього віку. Современная педиатрия. 4: 88—91.
5. Марушко РВ, Тищенко ВК. 2013. Особливості цитопротекторного потенціалу кишечнику у дітей раннього віку з функціональними та хронічними запальними захворюваннями кишечнику. Збірник наукових праць співробітників НМАПО ім. П.Л. Шупика. 22(3): 254—326.
6. Лукьянова ЕМ, Антипкин ЮГ, Янковский ДС и др. 2009. Микробная экологическая система человека и использование отечественных мультипробиотиков для профилактики и устранения ее у детей. Совр педиатрия. 4;26: 117—127.
7. Шадрін ОГ, Марушко РВ, Марушко ТЛ, Брюзгіна ТС. 2013. Характеристика спектра жирних кислот та шляхи його корекції у дітей раннього віку з функціональними та запальними захворюваннями кишечнику. Педіатрія, акушерство і гінекологія. 2: 53—57.
8. Шадрін ОГ, Дюкарева-Бездєнєжних СВ, Ковальчук А. 2012. Організація ентерального харчування в дітей. Дитячий лікар. 6: 16—18.
9. Albenberg LG, Lewis JD, Wu GD. 2012. Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol. 28;4: 314—320. http://dx.doi.org/10.1097/MOG.0b013e328354586f; PMid:22573192 PMCid:PMC3822011
10. Figler M, Gasztonyi B, Cseh J et al. 2007. Association of n53 and n56 long5chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel diseases. Br J Nutr. 97;6: 1154—1161. http://dx.doi.org/10.1017/S0007114507682956;PMid:17381967
11. Calder PC. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 75;3: 645—662. PMid:22765297 PMCid:PMC3575932
12. Chervonsky AV. 2012. Intestinal commensals: influence on immune system and tolerance to pathogens. Curr Opin Immunol. 24;3: 255—260. http://dx.doi.org/10.1016/j.coi.2012.03.002; PMid:22445718
13. Socha P, Ryzko J, Koletzko B et al. 2005. Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol. 40;5: 573—577. http://dx.doi.org/10.1080/00365520510012136; PMid:16036510
14. Rojas-Feria M, Castro E, Suеrez E et al. 2013. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 19;42: 7327—7340.
15. Hoa N, Prasadb V. 2013. Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Ann Gastroenterol. 26;3: 277—278.
16. Hisamatsu T, Kanai T, Mikami Y et al. 2013. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther. 137;3: 283—297. http://dx.doi.org/10.1016/j.pharmthera.2012.10.008; PMid:23103332
17. Calder PC, Kremmyda LS, Vlachava M et al. 2010. Is there a role for fatty acids in early life programming of the immune system? Proc Nutr Soc. 69;3: 373—380. http://dx.doi.org/10.1017/S0029665110001552; PMid:20462467
18. Viladomiu M, Hontecillas R, Yuan L. 2013. Nutritional protective mechanisms against gut inflammation. J Nutr Biochem. 24;6: 929—939. http://dx.doi.org/10.1016/j.jnutbio.2013.01.006; PMid:23541470 PMCid:PMC3730123
19. Sokol H, Seksik P. 2010. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr Opin Gastroenterol. 26;4: 327—331. http://dx.doi.org/10.1097/MOG.0b013e328339536b;PMid:20445446
20. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. 2014. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 11;2: 34—39. http://dx.doi.org/10.1111/apt.12794